RE:Simply Wall Street determines ONCY fair value at $157 p/sAt no time in the past has any stock analysis company like SWS determined that ONCY's fair value was worth $157 per share on a NPV of $ 8 billion US for ONCY in the mBC indication by itself.
Now that ONCY has potentially 2 Phase 3 cliical trials in breast and pancreatic cancer followed by pelareorep's application in combination with CAR-T, bispecifics or small molecules such as PARP and CDK4/6 inhibitors in multiple other cancer indications, the company's fair valuation will become a further point of interest with Big Pharma's increasing participation in the development of pelareorep.